利伐沙班和华法林治疗下肢深静脉血栓形成的疗效比较

Comparison of the Efficacy of Rivastaban and Warfarin in the Treatment of Deep Venous Thrombosis in Lower Extremities

目的比较利伐沙班和华法林治疗下肢深静脉血栓形成的疗效。方法收集该院在2016年3月—2017年3月收治的74例下肢深静脉血栓形成患者作为观察对象,通过单双号的分组方式分为对照组(37例)和实验组(37例),对照组应用华法林治疗,实验组应用利伐沙班治疗,分析和比较两组临床疗效和随访出血情况、静脉血栓复发情况。结果实验组治疗后1、2周D-二聚体水平和D-二聚体下降时间均明显优于对照组,其下肢深静脉血栓形成消失时间短于对照组,组间出现的差异有统计学意义(P<0.05);随访1年后实验组静脉血栓复发率低于对照组(P<0.05),但两组出血率差异无统计学意义(P>0.05)。结论与华法林相比,利伐沙班治疗下肢深静脉血栓形成效果显著,安全可行,值得广泛应用于临床。

Objective to compare the efficacy of Levashaban and warfarin in the treatment of deep venous thrombosis of lower extremity. Methods From March 2016 to March 2017, 74 patients with deep venous thrombosis of lower extremity were divided into control group(n=37) and experimental group(n=37) and control group(n=37), and the control group was treated with warfarin.The experimental group was treated with rivastaban. The clinical efficacy, follow-up bleeding and venous thrombus recurrence were analyzed and compared between the two groups. Results The level of D-dimer and the decrease time of D-dimer in the experimental group were significantly better than those in the control group at 1 week and 2 weeks after treatment The duration of deep venous thrombosis in lower extremity was shorter than that in the control group, and the differences between groups were statistically significant(P<0.05). After 1 year follow-up, the recurrence rate of venous thrombosis in the experimental group was lower than that in the control group(P<0.05), but there was no difference between the two groups(P>0.05). Conclusion Compared with warfarin, rivastaban is effective and safe in the treatment of deep venous thrombosis of lower extremity.